Tobramycin Injection, Solution
Product Images NDC 0409-3578

This text appears to be a chart displaying a reduced dosage nomogram for medication administration. The chart lists creatinine clearance values (in mL/min/1.73 m?) and corresponding percentages of normal, with recommended dosages from Table 3. Additionally, the chart includes serum creatinine values in mg/100 mL. The scales have been adjusted to facilitate dosage calculations.*

This is a description for a medicine that comes in a multiple-dose 2mlL container, with a National Drug Code (NDC) identification of 0409-3577-11. It is a pediatric prescription with a concentration of 20 mg/2 mL (10 mg/mL) and contains sulfites. It is labeled for LV or IM use, and it must be diluted for IV use. The medicine is distributed by Hospira, Inc. in Lake Forest, IL 60045 USA. The rest of the text is not relevant to the description.*

This is a label for a 20 mg/2 mL vial of medication that is intended for intramuscular or intravenous use. Dilution is necessary for intravenous use. The medication has been manufactured by Hospira, Inc, based in the United States and contains sulfites. The label also includes a barcode and product codes, but it is not clear what these codes are for.*

This is a medication with the brand name Tobramycinf#s, containing 80mg/2mL of an active ingredient that needs to be diluted for V use. It should be used with caution by individuals with sulfite allergies. The medication is distributed by Hospira, Inc. located in Lake Forest, IL, USA. There are several reference numbers on the packaging, including a National Drug Code (NDC) of 0409-3578-11, and other identifiers like FP0, 7.5 Mil, RL-7492, and HHE-HH#H-AA, which may be used for tracking and inventory purposes. The text also contains a warning and instructions to use the medicine for LV or M use only while also providing a prescription note.*

This appears to be a description of a medication in the form of an injection with a NDC (National Drug Code) number of 0409-3578-01. The injection is made in Hungary and distributed by Hospira, Inc. in the USA. The text includes a note that the medication must be diluted for intravenous use and is only available by prescription. There is also mention of a multiple-dose vial. The rest of the text is not legible and appears to be garbled.*